AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback